Osteoporotic vertebral compression fractures (OVCFs) have become a significant public health concern due to the high ...

The global kyphoplasty market size was US$ 632.45 million in 2021. The global kyphoplasty market size is forecast to reach US$ 1086.7 million by 2030, growing at a compound annual growth rate (CAGR) ...

Shrinking height in older adults is due to ageing. It could mean serious spinal fractures caused by bone loss over time.

Biocon Biologics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo and Evfraxy, biosimilars of ...

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...

Biocon said that Biocon Biologics has received marketing authorisations from UK Medicines and Healthcare products Regulatory Agency for Vevzuo and Evfraxy, biosimilars of Denosumab.

New Delhi: Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines ...

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

The plaintiff visited a popular Charlottesville bar owned by the corporate defendant, when the individual defendant — one of ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars Bengaluru, Karnataka, India, July 7, 2025  Biocon Biologics Ltd (BBL), a fully integrated global biosimilars ...

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).